Regentis Biomaterials Ltd. RGNT
Industrial Specialties · IPO 2025 · data as of November 13, 2026
Regentis Biomaterials Ltd. (RGNT) is a healthcare company listed in the US with a market value of about $9M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -93%.
About Regentis Biomaterials
Regentis Biomaterials is listed in the US and classified in industrial specialties, IPO year 2025. It was profitable in 1 of the last 3 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Net income | -$14M | $5M | -$4M |
| Free cash flow | — | -$641000 | — |
| EPS (diluted) | $-1.94 | $0.68 | $-0.59 |
| Net margin | — | — | — |
| ROIC | -92.7% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Regentis Biomaterials pay a dividend?
Not currently.
Is Regentis Biomaterials a good stock to buy?
We do not give buy or sell advice. Regentis Biomaterials scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.